Imbio nets FDA nod for RV/LV Analysis AI algorithm

By staff writers

March 16, 2021 -- Artificial intelligence (AI) software developer Imbio has garnered U.S. Food and Drug Administration (FDA) 510(k) clearance for RV/LV Analysis, a cardiothoracic imaging AI algorithm.

Designed to provide automated assessment of potential right ventricular dilation, RV/LV Analysis calculates the ratio of the maximum diameter of the right versus the left ventricle of the heart on CT pulmonary angiography exams, according to the vendor. This RV/LV ratio is a patient risk indicator for various pulmonary conditions, including pulmonary embolism, Imbio said.

The company said that the software's results are automatically available for clinicians; a full report of quantitative findings is added to the patient's imaging study within minutes.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking